Actinium Pharmaceuticals, Inc.
General ticker "ATNM" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $39.5M (TTM average)
Actinium Pharmaceuticals, Inc. does not follow the US Stock Market performance with the rate: -20.4%.
Estimated limits based on current volatility of 5.5%: low 0.97$, high 1.09$
Factors to consider:
- Total employees count: 25 (-32.4%) as of 2025
- Top business risk factors: Operational and conduct risks, Net losses, Capital raising failure, Clinical trial failure, Regulatory and compliance
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.18$, 3.21$]
- 2026-12-31 to 2027-12-31 estimated range: [1.39$, 3.56$]
Financial Metrics affecting the ATNM estimates:
- Positive: with PPE of -1.4 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Positive: Inventory ratio change, % of -99.74 <= -3.92
- Positive: 12.78 < Shareholder equity ratio, % of 15.13 <= 25.20
- Positive: Interest expense per share per price, % of 0 <= 0
- Negative: Industry earnings per price (median), % of -15.99 <= 0
- Positive: -1.23 < Investing cash flow per share per price, % of -0.22
- Positive: Industry inventory ratio change (median), % of 0 <= 0
Short-term ATNM quotes
Long-term ATNM plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.08MM | $0.00MM | $0.09MM |
| Operating Expenses | $52.00MM | $42.12MM | $36.34MM |
| Operating Income | $-51.92MM | $-42.12MM | $-36.25MM |
| Non-Operating Income | $3.10MM | $3.88MM | $2.36MM |
| R&D Expense | $38.67MM | $30.05MM | $21.12MM |
| Income(Loss) | $-48.82MM | $-38.24MM | $-33.89MM |
| Net Income(Loss)* | $-48.82MM | $-38.24MM | $-33.89MM |
| Stockholders Equity | $36.38MM | $32.76MM | $7.83MM |
| Assets | $81.44MM | $76.90MM | $51.77MM |
| Operating Cash Flow | $-47.34MM | $-33.07MM | $-24.58MM |
| Capital expenditure | $0.15MM | $0.01MM | $0.10MM |
| Investing Cash Flow | $-0.15MM | $-0.01MM | $-0.10MM |
| Financing Cash Flow | $14.87MM | $29.32MM | $-0.22MM |
| Earnings Per Share** | $-1.83 | $-1.27 | $-1.09 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.